Merck & Co., Inc. (NYSE:MRK) Stock Rating Raised to “Hold” at Zacks Research

Zacks Research upgraded shares of Merck & Co., Inc. (NYSE:MRK – Free Report) from a strong sell rating to a hold rating in a report issued on Tuesday morning,Zacks reports.

Other research analysts have also recently issued reports about the stock. The Goldman Sachs Group raised their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. HSBC upped their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Cantor Fitzgerald increased their target price on Merck & Co., Inc. from $145.00 to $155.00 and gave the company a “neutral” rating in a report on Monday, November 2nd. Sanford C. Bernstein raised their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th. Finally, Freedom Broker boosted their price target on Merck & Co., Inc. from $125.00 to $140.00 and gave the stock a “hold” rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $155.74.

Get Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $137.75 on Tuesday. The stock has a market cap of $339.59 billion, a price-to-earnings ratio of 142.01, a PEG ratio of 6.57 and a beta of 0.13. Merck & Co., Inc. has a 52 week low of $93.90 and a 52 week high of $156.92. The company’s 50-day moving average price is $145.73 and its 200 day moving average price is $129.11. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The company had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.58 earnings per share. As a group, research analysts forecast that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.

Merck & Co., Inc. Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.6%. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s dividend payout ratio is currently 350.52%.

Insider Activity

In other news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the sale, the executive vice president owned 112,955 shares in the company, valued at $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.17% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Large investors have recently added to or reduced their stakes in the business. Fi3 FINANCIAL ADVISORS LLC boosted its stake in Merck & Co., Inc. by 120.6% in the 3rd quarter. Fi3 FINANCIAL ADVISORS LLC now owns 7,671 shares of the company’s stock worth $1,121,000 after buying an additional 4,193 shares during the last quarter. Kensington Investment Counsel LLC grew its holdings in Merck & Co., Inc. by 1.5% in the 3rd quarter. Kensington Investment Counsel LLC now owns 37,875 shares of the company’s stock valued at $5,504,000 after buying an additional 550 shares during the period. Innovator Capital Management LLC acquired a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $19,922,000. Claris Financial LLC acquired a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $248,000. Finally, Coastal Bridge Advisors LLC increased its stake in shares of Merck & Co., Inc. by 122.4% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 47,019 shares of the company’s stock valued at $6,832,000 after acquiring an additional 25,878 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Top Merck & Co., Inc. Stories

These are some of the MRK stories that stood out recently:

  • Positive Sentiment: Merck and Isomorphic Labs will combine AI-based drug discovery with Merck’s research expertise to seek small-molecule candidates for an important oncology target. The collaboration could add to Merck’s future pipeline, though it is at an early discovery stage. Merck and Isomorphic Labs Enter Strategic Research Collaboration
  • Positive Sentiment: Recent pipeline updates include positive European regulatory opinions for expanded ENFLONSIA and WELIREG indications and Phase 2b results for efinopegdutide. These programs may help broaden growth beyond KEYTRUDA, although further development and regulatory steps remain. How Investors May Respond To Merck Pipeline Progress
  • Neutral Sentiment: Director Thomas H. Glocer plans to retire in May 2027, and Douglas M. Baker Jr. has been named independent lead director. The change appears to be a planned board transition, with no immediate business impact reported. Board Director Retirement and Appointment

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Further Reading

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.